TABLE 1

Nonspecific binding of validation set drugs and TKIs to HLM (0.25 mg/ml)

Drugfumic ± S.D. + CHAPS
(6 mM)fumic ± S.D. − CHAPSIonized at pH 7.4Log PPredicted fumic by SimCYPPredicted fumic by Austin et al. (2002)aPredicted fumic by Hallifax and Houston (2006)b
%
Validation set drugs
 Amitriptyline0.91 ± 0.030.64 ± 0.07994.81c–5.10d0.26–0.350.13–0.170.25–0.35
 Chlorpromazine0.72 ± 0.050.36 ± 0.06984.54c–5.20e0.26–0.450.11–0.230.21–0.47
 Felodipine0.26 ± 0.020.25 ± 0.0613.44c–4.83e0.39–0.770.17–0.550.35–0.82
 Isradipine0.75 ± 0.020.72 ± 0.0402.00c–4.30f0.55–0.950.29–0.890.56–0.95
 Loratidine0.47 ± 0.050.44 ± 0.0614.21d–5.94c0.15–0.560.05–0.310.06–0.60
 Midazolam0.83 ± 0.030.86 ± 0.06132.50f–3.97c0.64–0.910.38–0.800.68–0.93
 Nifedipine0.88 ± 0.030.87 ± 0.0211.82c–2.97e0.85–0.960.69–0.910.89–0.96
 Pazopanib0.73 ± 0.030.75 ± 0.0311.98e–3.59d0.74–0.950.50–0.890.78–0.95
 Zidovudine1.00 ± 0.021.01 ± 0.041000.53e–1.16c0.98–0.990.96–0.980.97–0.98
TKIs
 Axitinib0.79 ± 0.030.24.15c–4.20f0.58–0.590.31–0.330.60–0.62
 Dabrafenib0.81 ± 0.060.79 ± 0.02643.54e–5.46c0.33–0.750.08–0.520.14–0.79
 Erlotinib0.92 ± 0.020.89 ± 0.0312.39e–3.30f0.80–0.920.59–0.830.84–0.93
 Gefitinib0.76 ± 0.05223.75c–4.11e0.70–0.600.34–0.450.63–0.74
 Ibrutinib0.57 ± 0.04132.76d–3.63c0.73–0.890.49–0.750.77–0.91
 Lapatinib0.25 ± 0.02314.64c–5.18d0.30–0.450.11–0.210.22–0.42
 Nintedanib0.93 ± 0.03592.59e–3.70d0.72–0.910.47–0.780.76–0.92
 Nilotinib0.43 ± 0.0474.51d–5.36c0.25–0.490.09–0.230.17–0.48
 Regorafenib0.14 ± 0.030.14.20f–5.26e0.27–0.580.10–0.310.19–0.60
 Sorafenib0.14 ± 0.030.14.20f–5.16e0.30–0.580.12–0.310.23–0.60
 Trametinib0.58 ± 0.0202.68e–3.45d0.77–0.890.55–0.760.81–0.91
  • a Predicted values calculated using the equation fuinc = 1/C · 100.56 log P − 1.41 + 1.

  • b Predicted values calculated using the equation fuinc = 1/1 + C · 100.072(log P)2 + 0.067 ⋅ log P − 1.126.

  • c Marvin.

  • d ALOGPS2.1.

  • e ACD/Laboratories.

  • f XlogP3.